Mounjaro is the brand name of tirzepatide, a dual GIP and GLP-1 receptor agonist for type 2 diabetes. It is used with diet and exercise to improve glycemic control and is administered as a once-weekly subcutaneous injection. The FDA first approved it on May 13, 2022.
Wegovy and Mounjaro prices in South Korea are higher than in China and Japan. South Korea added both drugs to a non-insurance reporting system, but immediate price cuts are unlikely.
GLP-1 drugs used for type 2 diabetes and obesity are seeing rising demand for weight loss as safety concerns also draw attention. A 2025 WHO guideline said long-term safety data remains limited.
A Johns Hopkins study found GLP-1 users face increased dementia risk after a decade, possibly due to longer lifespan. A separate JCI review found GLP-1 drugs show neuroprotective signals in preclinical studies but consistent cognitive benefits in humans remain unproven.
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
The FDA has announced plans to crack down on active pharmaceutical ingredients used in compounded GLP-1 drugs and warned about the risks of these products. The agency has cited counterfeit products, non-FDA-approved ingredients and more than 1,000 adverse event reports tied to compounded semaglutide and tirzepatide.
Boots has launched an in-store weight loss service across 17 UK locations, offering face-to-face consultations for weight-loss injections like Wegovy and Mounjaro. The service includes a 10-week free weight loss programme and 12-month aftercare, with prices starting at £99.97 for Wegovy. This marks the first high street pharmacy to provide such in-person weight loss treatment consultations.
Soon-to-be brides and grooms in India are increasingly seeking Mounjaro and other weight-loss injections before weddings, with doctors reporting rising demand. The trend comes as India’s obesity-drug market expands, cheaper semaglutide versions enter the market, and regulators raise misuse concerns.
The FDA has approved Eli Lilly's GLP-1 weight loss pill Foundayo, which will compete with Novo Nordisk's Wegovy pill. Foundayo will be available through LillyDirect and pharmacies, with prices ranging from $25 with insurance to $149-$349 for cash payers. The approval sets up a new battle in the oral GLP-1 market between the two pharmaceutical giants.
Eli Lilly has acquired rights to CSL's IL-6 inhibitor clazakizumab in a $100 million deal, expanding its cardiometabolic pipeline. The monoclonal antibody targets chronic inflammation, particularly in cardiovascular conditions. This move follows Lilly's successful obesity and diabetes drugs that drove $65.1 billion in 2025 revenue.
Seven Indian pharmaceutical companies have launched generic semaglutide drugs at prices 70-80% lower than Novo Nordisk's Ozempic following patent expiration. Novo Nordisk has cut prices by 37% to maintain market share as competition intensifies in India's growing weight-loss drug market.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06734273 |
Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss |
RECRUITING | EARLY_PHASE1 |
| NCT06073184 |
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium |
NOT_YET_RECRUITING | PHASE2 |
